Land: Ierland
Taal: Engels
Bron: HPRA (Health Products Regulatory Authority)
Fipronil
Norbrook Laboratories (Ireland) Limited
QP53AX15
Fipronil
67 mg/pipette
Spot-on solution
POM: Prescription Only Medicine as defined in relevant national legislation
fipronil
Authorised
2012-07-06
Health Products Regulatory Authority 09 April 2019 CRN008ZTX Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Pestigon 67 mg Spot-On Solution for Small Dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One 0.67 ml pipette contains: ACTIVE SUBSTANCE: Fipronil 67 mg EXCIPIENTS: Butylhydroxyanisole (E320) 0.134 mg Butylhydroxytoluene (E321) 0.067 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Spot-on solution. A clear, colourless to pale yellow solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of infestations by fleas (_Ctenocephalides felis_). The product shows immediate insecticidal effect and persistent insecticidal activity against new infestations by adult fleas for up to 8 weeks. The product has a persistent acaricidal efficacy against _Ixodes ricinus _for up to 2 weeks, _Rhipicephalus sanguineus _for up to 3 weeks and _Dermacentor reticulatus _for up to 4 weeks. If ticks of these species are present when the product is applied, all ticks will not be killed within the first 48 hours but they may be killed within a week. The product can be used as part of a treatment programme for Flea Allergy Dermatitis where this has been previously diagnosed by a Veterinary Surgeon. 4.3 CONTRAINDICATIONS Do not use in dogs weighing less than 2 kg. In the absence of available data, the product should not be used in puppies less than 8 weeks old. Do not use in sick (systemic diseases, fever…) or convalescent animals. Do not use in rabbits, as adverse reactions and even death could occur. This product is specifically developed for dogs. Do not use in cats, as this could lead to overdosing. Do not use in cases of known hypersensitivity to the active or to any of the excipients. Health Products Regulatory Authority 09 April 2019 CRN008ZTX Page 2 of 5 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES The product does not prevent ticks from a Lees het volledige document